Related Experiment Videos
Testicular function after radioiodine therapy for thyroid carcinoma
1Department of Clinical Biochemistry, University of Bonn, Germany. maria.wichers@gmx.de
European Journal of Nuclear Medicine
|June 15, 2000
Summary
Radioiodine therapy for thyroid cancer temporarily impairs testicular function, indicated by elevated FSH and reduced inhibin B, suggesting reduced sperm production. However, full recovery of gonadal function is observed 18 months post-treatment.
Area of Science:
- Endocrinology
- Oncology
- Reproductive Medicine
Background:
- Radiotherapy, including radioiodine therapy, is a known risk factor for infertility.
- Limited data exist on the specific impact of radioiodine therapy for thyroid carcinoma on male testicular function.
Purpose of the Study:
- To prospectively investigate the longitudinal effects of radioiodine therapy on testicular function in men with differentiated thyroid carcinoma.
Main Methods:
- A longitudinal study involving 25 men with differentiated thyroid carcinoma.
- Hormonal assessments (FSH, inhibin B, LH, testosterone) were performed before and at multiple time points (3, 6, 12, 18 months) after radioiodine therapy.
- Analysis of hormonal changes to evaluate testicular function, including spermatogenesis and Leydig cell function.
Main Results:
- Significant increases in Follicle-Stimulating Hormone (FSH) and decreases in inhibin B were observed 3 and 6 months post-therapy, indicating impaired spermatogenesis.
- Luteinising Hormone (LH) and testosterone levels showed transient changes, suggesting compensated Leydig cell function.
- Hormonal profiles returned to baseline levels by 18 months, indicating complete recovery of gonadal function.
Conclusions:
- Radioiodine therapy for thyroid cancer causes temporary, significant impairment of spermatogenesis and compensated Leydig cell insufficiency.
- Testicular function demonstrates complete recovery by 18 months after radioiodine therapy.